




RECEIVED
AUG 25 2003
TECH CENTER 1600/2300

Due Date:

Applicant: STADDON *et al.* **Art Unit:** To be assigned
Application No.: (To be assigned; Continuation of U.S. Appl. No. 08/648,182) **Examiner:** To be assigned
Filed: HEREWITH (May 4, 2001) **Docket:** 0623.0410001
For: Use of an Agent Which Modulates Tyrosine Phosphorylation for Modulating the Permeability of a Psychological Barrier **Atty:** EKS/BJD

When receipt stamp is placed hereon, the USPTO acknowledges receipt of the following documents:

1. PTO Utility Patent Application Transmittal (Form PTO/SB/05); PTO Fee Transmittal Form (PTO/SB/17) (in duplicate); Our check No. 31188 for \$1,532.00 to cover; (\$710.00) filing fee for patent application, and (\$882.00) fee for excess claims; Application Data Sheet; A copy of the executed Declaration, as originally filed in U.S. Appl. No. 08/648,182 (3 pages); Authorization to Treat a Reply As Incorporating An Extension of Time Under 37 C.F.R. § 1.136(a)(3) (in duplicate); Letter to PTO Draftsman: Submission of Formal Drawings with 4 sheets of formal drawings attached; Preliminary Amendment and Submission of Sequence Listing, with attached substitute page 1 (title page), and substitute page 72 (Abstract); A computer readable copy of the sequence listing with 4 pages of a paper copy of a sequence listing; U.S. Utility Continuation Patent Application entitled: Use of an Agent Which Modulates Tyrosine Phosphorylation for Modulating the Permeability of a Psychological Barrier and naming as inventors: James Martin STADDON, Lee Laurence RUBIN, Kurt HERRENKNECHT, and Mary Louise MORGAN; the application consisting of a total of 71 pages: A specification containing: 68 pages of description prior to the claims; 3 pages of claims (20 claims); and 19 sheets of drawings: (Figures 1A-C, 2A-B, 3A-B, 4A-D, 4.1, 5A-D, 5.1, 5.2, 6A-G, 7/9, 8, 10A-F, 11A-B/12A-B, 13A-B/15, 14, 17A-D, 18A-H, and 19); and Two (2) return postcards.



Box: Patent Application

Please Date Stamp And Return To Our Courier

OCT 15 2003
AUG 20 2003
U.S. PATENT & TRADEMARK OFFICE

THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

STADDON *et al.*

Appl. No.: (To be assigned; Continuation of
U.S. Appl. No. 08/648,182)

Filed: (Herewith)

For: **Use of an Agent Which Modulates
Tyrosine Phosphorylation for
Modulating the Permeability of a
Psychological Barrier**

Art Unit: (To Be Assigned)

Examiner: (To Be Assigned)

Atty. Docket: 0623.0410001/EKS/BJD

**Preliminary Amendment
and Submission of Sequence Listing**

RECEIVED
AUG 25 2003
TECH CENTER 1600/2900

Commissioner for Patents
Washington, D.C. 20231

Sir:

In advance of prosecution in the above identified matter, Applicants submit the following amendments and remarks. This Preliminary Amendment is provided in the following format:

- (A) A clean version of each replacement paragraph/section/claim along with clear instructions for entry;
- (B) Starting on a separate page, appropriate remarks. *See 37 C.F.R. § 1.121 and MPEP § 714; and*
- (C) Starting on a separate page, a marked-up version entitled: "Version with markings to show changes made."

It is not believed that extensions of time or fees for net addition of claims are required beyond those that may otherwise be provided for in documents accompanying this paper. However, if additional extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R. § 1.136(a), and

any fees required therefor (including fees for net addition of claims) are hereby authorized to be charged to our Deposit Account No. 19-0036.

Amendments

In the Title:

Please delete the Title of the application and substitute therefor the following Title:

Modulating the Permeability of a Physiological Barrier With an Agent that Modulates Tyrosine Phosphorylation .

In the Specification:

Please amend the specification as follows:

Please delete page 1 of the specification, and substitute therefor page 1 that is appended hereto as a substitute page.

At page 5, please delete the paragraph appearing at lines 8-18, and substitute therefor the following paragraph:

BRIEF SUMMARY OF THE INVENTION

The present invention is based, in contrast, on the surprising discovery that tyrosine protein phosphorylation is crucial to the control of the permeability of tight junctions in both epithelial and endothelial cells; tyrosine protein phosphorylation may therefore be manipulated to control